-+ 0.00%
-+ 0.00%
-+ 0.00%

Fosun Pharmaceutical (600196.SH) subsidiary DM1001 formulation approved for clinical trials

Zhitongcaijing·07/24/2026 08:57:08
Listen to the news

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) issued an announcement. Recently, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. (“Fosun Wanbang”), a holding subsidiary of the company, received approval from the State Drug Administration to conduct clinical trials for the treatment of signs and symptoms of idiopathic Parkinson's disease in adults. Fosun Wanbang plans to conduct phase I clinical trials of this drug in China when conditions are met. This drug is a chemical drug. According to the latest IQVIA CHPA data, in 2025, sales of drugs with the same compound in China will be approximately 375 million yuan.